Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$43.19 +0.5%	$45.75	$40.53 ▼ $75.71	$5.11B	0.95	1.51 million shs	1.52 million shs
ITCI Intra-Cellular Therapies	$131.81 +0.0%	$129.12	$64.09 ▼ $131.87	$14.04B	0.69	1.39 million shs	1.58 million shs
SMMT Summit Therapeutics	$20.32 -1.4%	$20.51	$2.10 ▼ $33.89	$14.99B	-1.04	3.43 million shs	1.69 million shs
TEVA Teva Pharmaceutical Industries	$15.06 -2.8%	$17.21	$12.51 ▼ $22.80	$17.07B	0.82	9.65 million shs	7.84 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	+0.47%	-4.93%	-7.83%	-8.80%	-39.52%
ITCI Intra-Cellular Therapies	+0.05%	+0.12%	+2.61%	+55.34%	+89.06%
SMMT Summit Therapeutics	-1.36%	+2.89%	+11.04%	+11.59%	+441.87%
TEVA Teva Pharmaceutical Industries	-3.02%	-6.92%	-10.33%	-33.88%	+4.26%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTK Cytokinetics	3.967 of 5 stars	4.5	1.0	0.0	4.6	2.2	0.8	0.0
ITCI Intra-Cellular Therapies	3.5981 of 5 stars	2.2	3.0	0.0	4.5	3.0	1.7	0.6
SMMT Summit Therapeutics	2.8115 of 5 stars	4.5	2.0	0.0	0.0	2.5	1.7	0.0
TEVA Teva Pharmaceutical Industries	2.5105 of 5 stars	3.4	3.0	0.8	0.0	2.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.94	Moderate Buy	$82.00	89.86% Upside
ITCI Intra-Cellular Therapies	2.47	Hold	$106.08	-19.52% Downside
SMMT Summit Therapeutics	3.00	Buy	$35.44	74.43% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	55.62% Upside

Current Analyst Ratings Breakdown

Latest CYTK, TEVA, SMMT, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2025	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$23.00 ➝ $35.00
3/21/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/12/2025	SMMT Summit Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/7/2025	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$67.00
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00
2/28/2025	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00
2/28/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
2/25/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00
2/24/2025	ITCI Intra-Cellular Therapies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$140.00 ➝ $132.00
2/21/2025	ITCI Intra-Cellular Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/13/2025	CYTK Cytokinetics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$70.00 ➝ $67.00

(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	276.83	N/A	N/A	($3.94) per share	-10.96
ITCI Intra-Cellular Therapies	$680.50M	20.63	N/A	N/A	$6.15 per share	21.43
SMMT Summit Therapeutics	$700K	21,413.80	N/A	N/A	$0.11 per share	184.73
TEVA Teva Pharmaceutical Industries	$16.54B	1.03	$2.98 per share	5.05	$4.75 per share	3.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$526.24M	-$5.26	N/A	N/A	N/A	-17,906.25%	N/A	-50.21%	5/6/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	693.74	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.31	N/A	N/A	N/A	N/A	-85.42%	-52.66%	4/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.72	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest CYTK, TEVA, SMMT, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/27/2025	Q4 2024	CYTK Cytokinetics	-$1.29	-$1.26	+$0.03	-$1.26	$14.26 million	$16.93 million
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.72%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	5.93	9.28	9.28
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	3.40%
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	88.30%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	118.41 million	114.00 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	737.68 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

CYTK, TEVA, SMMT, and ITCI Headlines

Recent News About These Companies

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

March 28 at 6:11 AM | fool.com

Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Hold at StockNews.com

March 28 at 3:09 AM | americanbankingnews.com

Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win

March 27 at 6:28 PM | msn.com

Teva to Host Conference Call to Discuss First [...]

March 27 at 6:28 PM | aktiencheck.de

Teva Pharmaceutical Industries Ltd: Teva Releases Q1 2025 Aide Memoire

March 27 at 6:28 PM | finanznachrichten.de

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27 at 4:45 PM | financialpost.com

Teva Releases Q1 2025 Aide Memoire

March 27 at 4:45 PM | financialpost.com

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27 at 4:30 PM | globenewswire.com

Teva Releases Q1 2025 Aide Memoire

March 27 at 4:30 PM | globenewswire.com

Drugmakers accused of a price-fixing scheme have agreed to a $49M settlement, state says

March 27 at 1:27 PM | yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded to "Hold" Rating by StockNews.com

March 27 at 2:05 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Sound Shore Management Inc. CT's 3rd Largest Position

March 25, 2025 | marketbeat.com

Emerald Advisers LLC Has $1.10 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 25, 2025 | marketbeat.com

KLP Kapitalforvaltning AS Takes $8.97 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 25, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

March 24, 2025 | fool.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Boston Partners

March 24, 2025 | marketbeat.com

Teacher Retirement System of Texas Raises Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 23, 2025 | marketbeat.com

Blueshift Asset Management LLC Cuts Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 22, 2025 | marketbeat.com

iA Global Asset Management Inc. Sells 85,772 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 22, 2025 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at StockNews.com

March 22, 2025 | americanbankingnews.com

2TEVA : Teva Pharmaceutical Indus's Options: A Look at What the Big Money is...

March 21, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, TEVA, SMMT, and ITCI Company Descriptions

Cytokinetics NASDAQ:CYTK

$43.19 +0.20 (+0.47%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$43.18 0.00 (-0.01%)

As of 03/28/2025 05:20 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Intra-Cellular Therapies NASDAQ:ITCI

$131.81 +0.06 (+0.05%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$131.84 +0.03 (+0.03%)

As of 03/28/2025 06:12 PM Eastern

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$20.32 -0.28 (-1.36%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$20.52 +0.20 (+0.98%)

As of 03/28/2025 07:56 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$15.06 -0.44 (-2.81%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$15.07 +0.02 (+0.13%)

As of 03/28/2025 07:57 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time